The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Davison, Jon M ^a   Yee, Melissa ^a   Krill Burger, J Michael ^a   Lyons Weiler, Maureen A ^a   Kelly, Lori A ^a   Sciulli, Christin M ^a   Nason, Katie S ^a   Luketich, James D ^a   Michalopoulos, George K ^a   LaFramboise, William A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CDK6 GENE; CDKN2A GENE; CDKN2B GENE; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE; GENE DOSAGE; GENETIC GAIN; GENETIC IDENTIFICATION; HER2 GENE; HUMAN; HUMAN TISSUE; MALE; MET GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PATHOGENESIS; PREDICTION; QUANTITATIVE ANALYSIS; RUNX1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMAD4 GENE; WWOX GENE;

ADENOCARCINOMA; AGED; ANEUPLOIDY; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84898618014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079079     Document Type: Article

References (57)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289.
2. Pohl H, Sirovich B, Welch HG (2010) Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19: 1468-1470.
3. Rice TW, Rusch VW, Ishwaran H, Blackstone EH (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 116: 3763-3773.
4. Schweigert M, Dubecz A, Stein HJ (2013) Oesophageal cancer-an overview. Nat Rev Gastroenterol Hepatol.
5. Pech O, Bollschweiler E, Manner H, Leers J, Ell C, et al. (2011) Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 254: 67-72.
6. Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, et al. (2009) Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 137: 815-823.
7. Rice TW, Blackstone EH, Goldblum JR, DeCamp MM, Murthy SC, et al. (2001) Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 122: 1077-1090.
8. Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, et al. (2005) Early esophageal cancer: pattern of lymphatic spread and prognostic factors for longterm survival after surgical resection. Ann Surg 242: 566-573; discussion 573-565.
9. Theisen J, Feith M, Stein HJ, Siewert JR (2007) Management of early esophageal cancer. Adv Surg 41: 229-239.
10. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
11. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol 9: M57-60.
12. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481: 306-313.
13. Reid BJ (2010) Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark 9: 307-324.
14. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, et al. (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72: 4383-4393.
15. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, et al. (2010) Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 3: 1176-1186.
16. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, et al. (2011) Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 60: 1317-1326.
17. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, et al. (2008) Genome-wide copy number analysis in esophageal adenocarcinoma using highdensity single-nucleotide polymorphism arrays. Cancer Res 68: 4163-4172.
18. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45: 478-486.
19. Deng N, Goh LK, Wang H, Das K, Tao J, et al. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684.
20. Araujo SE, Bernardo WM, Habr-Gama A, Kiss DR, Cecconello I (2007) DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 50: 1800-1810. (Pubitemid 350077095)
21. Choma D, Daures JP, Quantin X, Pujol JL (2001) Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer 85: 14-22. (Pubitemid 32695710)
22. Sarbia M, Molsberger G, Willers R, Horstmann O, Schroders C, et al. (1996) The prognostic significance of DNA ploidy in adenocarcinomas of the esophagogastric junction. J Cancer Res Clin Oncol 122: 186-188. (Pubitemid 26076889)
23. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, et al. (1994) Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 73: 1785-1794. (Pubitemid 24101951)
24. Menke-Pluymers MB, Hop WC, Mulder AH, Tilanus HW (1995) DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Hepatogastroenterology 42: 786-788. (Pubitemid 26026433)
25. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, et al. (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71: 1858-1870.
26. Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, et al. (2013) Genomic variation by whole-genome SNP mapping arrays predicts timeto-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes. J Mol Diagn 15: 196-209.
27. Hirsch D, Kemmerling R, Davis S, Camps J, Meltzer PS, et al. (2013) Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. Cancer Res 73: 1454-1460.
28. Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101: 8699-8704. (Pubitemid 38745834)
29. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, et al. (2011) Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 20: 2183-2194.
30. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, et al. (2011) Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 71: 3447-3452.
31. Baumbusch LO, Helland A, Wang Y, Liestol K, Schaner ME, et al. (2013) High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One 8: e54356.
32. Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, et al. (2008) Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays. Genes Chromosomes Cancer 47: 957-964.
33. Thompson ER, Herbert SC, Forrest SM, Campbell IG (2005) Whole genome SNP arrays using DNA derived from formalin-fixed, paraffin-embedded ovarian tumor tissue. Hum Mutat 26: 384-389. (Pubitemid 41361806)
34. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006. (Pubitemid 34662293)
35. Ong CA, Shapiro J, Nason KS, Davison JM, Liu X, et al. (2013) Three-Gene Immunohistochemical Panel Adds to Clinical Staging Algorithms to Predict Prognosis for Patients With Esophageal Adenocarcinoma. J Clin Oncol.
36. Radu OM, Foxwell T, Cieply K, Navina S, Dacic S, et al. (2012) HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol 137: 583-594.
37. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
38. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
39. Jacobsen CM, Narita N, Bielinska M, Syder AJ, Gordon JI, et al. (2002) Genetic mosaic analysis reveals that GATA-4 is required for proper differentiation of mouse gastric epithelium. Dev Biol 241: 34-46. (Pubitemid 34066760)
40. Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, et al. (2002) Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem 277: 31909-31917. (Pubitemid 34968999)
41. Lango Allen H, Flanagan SE, Shaw-Smith C, De Franco E, Akerman I, et al. (2012) GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet 44: 20-22.
42. Fu B, Luo M, Lakkur S, Lucito R, Iacobuzio-Donahue CA (2008) Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. Cancer Biol Ther 7: 1593-1601.
43. Lin L, Bass AJ, Lockwood WW, Wang Z, Silvers AL, et al. (2012) Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proc Natl Acad Sci U S A 109: 4251-4256.
44. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, et al. (2011) RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 29: 1364-1372.
45. Saldivar JC, Shibata H, Huebner K (2010) Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem 109: 858-865.
46. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM (2007) WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med 13: 12-22.
47. Lai LA, Kostadinov R, Barrett MT, Peiffer DA, Pokholok D, et al. (2010) Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res 8: 1084-1094.
48. Ng G, Huang J, Roberts I, Coleman N (2006) Defining ploidy-specific thresholds in array comparative genomic hybridization to improve the sensitivity of detection of single copy alterations in cell lines. J Mol Diagn 8: 449-458. (Pubitemid 44377927)
49. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C (2012) Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 13: 528-538.
50. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048. (Pubitemid 44325930)
51. Janssen A, Kops GJ, Medema RH (2009) Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 106: 19108-19113.
52. Bayraktar S, Gluck S (2012) Systemic therapy options in BRCA mutationassociated breast cancer. Breast Cancer Res Treat 135: 355-366.
53. Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, et al. (2013) Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res 23: 217-227.
54. Korbel JO, Campbell PJ (2013) Criteria for inference of chromothripsis in cancer genomes. Cell 152: 1226-1236.
55. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
56. Li S, Hsu DD, Wang H, Feng GS (2012) Dual faces of SH2-containing proteintyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front Med 6: 275-279.
57. Marx AH, Zielinski M, Kowitz CM, Dancau AM, Thieltges S, et al. (2010) Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 57: 418-426.